Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Shore ND, Fizazi K, Schweizer MT, Castro E, Azad AA, George DJ, da Trindade KM, Zeng H, Shrivastava N, Tonkovyd S, Bock A, Nekkalapudi S, Tang Y, Lin S, Agarwal N

Open source

DOI: 10.1080/14796694.2026.2667441
Published: 2026 May
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2667441,
  title = {Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.},
  author = {Shore ND and Fizazi K and Schweizer MT and Castro E and Azad AA and George DJ and da Trindade KM and Zeng H and Shrivastava N and Tonkovyd S and Bock A and Nekkalapudi S and Tang Y and Lin S and Agarwal N},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2667441},
  url = {https://doi.org/10.1080/14796694.2026.2667441}
}

RIS

TY  - JOUR
TI  - Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.
AU  - Shore ND
AU  - Fizazi K
AU  - Schweizer MT
AU  - Castro E
AU  - Azad AA
AU  - George DJ
AU  - da Trindade KM
AU  - Zeng H
AU  - Shrivastava N
AU  - Tonkovyd S
AU  - Bock A
AU  - Nekkalapudi S
AU  - Tang Y
AU  - Lin S
AU  - Agarwal N
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2667441
UR  - https://doi.org/10.1080/14796694.2026.2667441
ER  -

APA

ND, S., K, F., MT, S., E, C., AA, A., DJ, G., KM, D. T., H, Z., N, S., S, T., A, B., S, N., Y, T., S, L., & N, A. (2026). Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2667441

Source records

pubmed · retrieved 2026-09-25T17:54:56.640Z